MedTrace Logo

SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers

NCT07080619 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-09-11

No results posted yet for this study

Summary

This study is an open-label, multicenter Phase IIa trial to evaluate the efficacy and safety of SC-101 monotherapy in patients with locally advanced or metastatic malignant tumors who are positive for NECTIN4 gene amplification.

Conditions

  • TNBC - Triple-Negative Breast Cancer
  • HR+ Breast Cancer

Interventions

DRUG

SC-101

Receive 7.5 mg/m² of SC-101 intravenously once weekly (QW).

Sponsors & Collaborators

  • Tianjin ConjuStar Biologics Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-20
Primary Completion
2027-07-30
Completion
2027-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07080619 on ClinicalTrials.gov